stay up to date on this topic
beverly henry had accepted death, what was harder to accept was the assault that her rare and aggressive form of cancer was taking on her appearance.
huge sores, one the size of a ripe avocado on her forehead, covered the 62-year-old’s body; when she did still have to go out, it was with a mask and a hood.
chemotherapy sessions had achieved nothing and she was given days to live, when henry suddenly got a call from the new hematology research unit (hru) at vancouver general hospital in mid-march to undertake a clinical trial with drugs never before administered in b.c.
“my last week at home, my mom didn’t see me because i was upstairs in bed, there was nothing left in me,” henry said. “when i came down and i got that phone call to come to vgh, and my mom saw me, there was horror in her face just to see how much i’d deteriorated in a week’s time.”
henry had been diagnosed with acute myeloid
leukemia in november, and when her specific subtype didn’t respond to multiple rounds of chemo, her doctors ran out of conventional treatment options.
so what they did, her hematologist said, was speed up the activation of an early phase clinical trial specifically designed for henry’s subtype of acute myeloid
leukemia.
her medical team were stunned at the results.
“i didn’t expect that this drug would give me back six weeks of time that i didn’t really have,” henry said. “there was a good chance i was going to come in here and it was too late. but here i am.
“don’t give up hope that someone is going to walk through the door today and you might get the same chance that i have.”
when henry was admitted to the trial, leukemia was visible on her skin from head to toe, said
dr. florian kuchenbauer, a clinician scientist dealing in leukemia and bone marrow transplants at vgh.
“we were not sure if she would survive the next days,” he said. “remarkably, she responded so well to the investigational treatment that she became nearly unrecognizable, in the best way.